Role of background metformin therapy in cardiorenal outcomes in type 2 diabetic patients treated with SGLT2 inhibitors

Role of background metformin therapy in cardiorenal outcomes in type 2 diabetic patients treated with SGLT2 inhibitors - Role of background metformin therapy in cardiorenal outcomes in type 2 diabetic patients treated with SGLT2 inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060509

Enrollment

220

Registered

2026-02-01

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with T2DM (age >=18 y/o) who visited our outpatient clinic between April 2014 and September 2018 and were newly given SGLT2 inhibitors

Exclusion criteria

Exclusion criteria: Patients on steroid therapy or immunosuppressive agents and those with multiple missing data

Design outcomes

Primary

Measure	Time frame
Is there any differences in the occurence of major adverse cardiovascular events (MACE), defined as acute myocardial infarction, stroke, or cardiovascular death, according to background antidiabetic therapy	—

Secondary

Measure	Time frame
Are there any differences in the occurence of MACE, hospitalization for heart failure and renal events (>=30% decline in estimated glomerular filtration rate or end-stage kidney disease), according to background antidiabetic therapy. We also evaluated the association of Fibrosis index 4 and those events.	—

Countries

Japan

Contacts

Public ContactKeisuke Takano

Tokyo Bay Urayasu Ichikawa Medical Center Department of Nephrology, Endocrinology and Diabetes

kt900928@gmail.com047-351-3101

Outcome results